{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:02:12Z","timestamp":1793084532201,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s43440-025-00770-1","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T02:44:59Z","timestamp":1756781099000},"page":"45-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epigenetic modulation in cancer drug discovery: promising targets and clinical applications"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-1575","authenticated-orcid":false,"given":"Sundaram","family":"Vickram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shofia Saghya","family":"Infant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-2269","authenticated-orcid":false,"given":"Manikandan","family":"Sivasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5420-8662","authenticated-orcid":false,"given":"Saravanan","family":"Anbalagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-3449","authenticated-orcid":false,"given":"Mathan Muthu Chinnakannu","family":"Marimuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0934-0816","authenticated-orcid":false,"given":"Hitesh","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"1","key":"770_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-023-01333-7","volume":"8","author":"YL Wu","year":"2023","unstructured":"Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, Guo B, et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduct Target Ther. 2023;8(1):98. https:\/\/doi.org\/10.1038\/s41392-023-01333-7.","journal-title":"Signal Transduct Target Ther"},{"key":"770_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/bs.pmbts.2023.01.001","volume":"197","author":"S Acharjee","year":"2023","unstructured":"Acharjee S, Chauhan S, Pal R, Tomar RS. Mechanisms of DNA methylation and histone modifications. Prog Mol Biol Transl Sci. 2023;197:51\u201392. https:\/\/doi.org\/10.1016\/bs.pmbts.2023.01.001.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5","key":"770_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrclinonc.2013.42","volume":"10","author":"CA N.Azad","year":"2013","unstructured":"N.Azad CA, Zahnow CM, Rudin SB, Baylin. The future of epigenetic therapy in solid tumours\u2014lessons from the past. Nat Reviews Clin Oncol. 2013;10(5):256\u201366. https:\/\/doi.org\/10.1038\/nrclinonc.2013.42.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"12","key":"770_CR4","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1021\/acs.molpharmaceut.3c00610","volume":"20","author":"A Ghosh","year":"2023","unstructured":"Ghosh A, Himaja A, Biswas S, Kulkarni O, Ghosh B. Advances in the delivery and development of epigenetic therapeutics for the treatment of cancer. Mol Pharm. 2023;20(12):5981\u20136009.","journal-title":"Mol Pharm"},{"key":"770_CR5","doi-asserted-by":"publisher","unstructured":"Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277. https:\/\/doi.org\/10.1016\/j.lfs.2021.119504.","DOI":"10.1016\/j.lfs.2021.119504"},{"issue":"8","key":"770_CR6","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.4103\/1673-5374.332145","volume":"17","author":"F Copped\u00e8","year":"2022","unstructured":"Copped\u00e8 F. Targeting the epigenome to treat neurodegenerative diseases or delay their onset: a perspective. Neural Regen Res. 2022;17(8):1745\u20137. https:\/\/doi.org\/10.4103\/1673-5374.332145.","journal-title":"Neural Regen Res"},{"key":"770_CR7","doi-asserted-by":"publisher","unstructured":"Li L, Chen R, Zhang H, Li J, Huang H, Weng J, Tan H, et al. The epigenetic modification of DNA methylation in neurological diseases. Front Immunol. 2024;15:1401962. https:\/\/doi.org\/10.3389\/fimmu.2024.1401962.","DOI":"10.3389\/fimmu.2024.1401962"},{"issue":"1","key":"770_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/jfb16010024","volume":"16","author":"N Parvin","year":"2025","unstructured":"Parvin N, Joo SW, Mandal TK. Biodegradable and Stimuli-Responsive nanomaterials for targeted drug delivery in autoimmune diseases. J Funct Biomater. 2025;16(1):24. https:\/\/doi.org\/10.3390\/jfb16010024.","journal-title":"J Funct Biomater"},{"key":"770_CR9","doi-asserted-by":"publisher","unstructured":"Strzelec M, Detka J, Mieszczak P, Soboci\u0144ska MK, Majka M. Immunomodulation\u2014a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol. 2023;14:1127704. https:\/\/doi.org\/10.3389\/fimmu.2023.1127704.","DOI":"10.3389\/fimmu.2023.1127704"},{"issue":"3","key":"770_CR10","first-page":"121","volume":"45","author":"T Koento","year":"2023","unstructured":"Koento T, Reksodiputro MH, Yosia M. Unravelling the genetic and epigenetic symphony: a narrative review exploring the interplay in etiology of microtia. Rev Esp Cir Oral Maxilofac. 2023;45(3):121\u20137.","journal-title":"Rev Esp Cir Oral Maxilofac"},{"issue":"2","key":"770_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/genes12020208","volume":"12","author":"A Majchrzak-Celi\u0144ska","year":"2021","unstructured":"Majchrzak-Celi\u0144ska A, Warych A, Szoszkiewicz M. Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing. Genes. 2021;12(2):208. https:\/\/doi.org\/10.3390\/genes12020208.","journal-title":"Genes"},{"key":"770_CR12","doi-asserted-by":"crossref","unstructured":"Wu Z, Zhang W, Qu J, Liu GH. Emerging epigenetic insights into aging mechanisms and interventions. Trends Pharmacol Sci. (2024).","DOI":"10.1016\/j.tips.2023.12.002"},{"key":"770_CR13","doi-asserted-by":"publisher","first-page":"1218986","DOI":"10.3389\/fcell.2023.1218986","volume":"11","author":"CP Sousa","year":"2023","unstructured":"Sousa CP, Soares CM, Chin D, Trisciuoglio F, Valdes-Mora. Editorial: epigenetic therapy against cancer: toward new molecular targets and technologies. Front Cell Dev Biol. 2023;11:1218986. https:\/\/doi.org\/10.3389\/fcell.2023.1218986.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"770_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/ph14070641","volume":"14","author":"VG Sorrentino","year":"2021","unstructured":"Sorrentino VG, Thota S, Gonzalez EA, Rameshwar P, Chang VT, Etchegaray JP. Hypomethylating chemotherapeutic agents as therapy for myelodysplastic syndromes and prevention of acute myeloid leukemia. Pharmaceuticals. 2021;14(7):641. https:\/\/doi.org\/10.3390\/ph14070641.","journal-title":"Pharmaceuticals"},{"key":"770_CR15","doi-asserted-by":"crossref","unstructured":"Rangwala S, Duvic M, Zhang C. Trends in the treatment of cutaneous T-cell lymphoma\u2013critical evaluation and perspectives on vorinostat. Blood and Lymphatic Cancer: Targets and Therapy. 2012;17\u201327.","DOI":"10.2147\/BLCTT.S15564"},{"issue":"2","key":"770_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jpha.2022.11.009","volume":"13","author":"Q Liao","year":"2023","unstructured":"Liao Q, Yang J, Ge S, Chai P, Fan J, Jia R. Novel insights into histone lysine methyltransferases in cancer therapy: from epigenetic regulation to selective drugs. J Pharm Anal. 2023;13(2):127\u201341. https:\/\/doi.org\/10.1016\/j.jpha.2022.11.009.","journal-title":"J Pharm Anal"},{"issue":"10","key":"770_CR17","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/cancers11101483","volume":"11","author":"D Reyes-Garau","year":"2019","unstructured":"Reyes-Garau D, Ribeiro ML, Rou\u00e9 G. Pharmacological targeting of BET bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications. Cancers. 2019;11(10):1483. https:\/\/doi.org\/10.3390\/cancers11101483.","journal-title":"Cancers"},{"key":"770_CR18","doi-asserted-by":"publisher","unstructured":"Li M, Ye J, Xia Y, Li M, Li M, Hu GX et al. METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4. Leukemia. 2022;36(11):2586\u201395. https:\/\/doi.org\/10.1038\/s41375-022-01696-w","DOI":"10.1038\/s41375-022-01696-w"},{"key":"770_CR19","unstructured":"Yanis Boumber MD, Issa JPJ. Epigenetics in cancer: what\u2019s the future? Oncology. 2011;25(3):220."},{"issue":"1","key":"770_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","volume":"12","author":"Y Fang","year":"2019","unstructured":"Fang Y, Liao G, Yu B. LSD1\/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019;12(1):129. https:\/\/doi.org\/10.1186\/s13045-019-0811-9.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"770_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41416-023-02276-0","volume":"129","author":"AB El-Khoueiry","year":"2023","unstructured":"El-Khoueiry AB, Clarke J, Neff T, Crossman T, Ratia N, Rathi C, et al. Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors. Br J Cancer. 2023;129(2):309\u201317. https:\/\/doi.org\/10.1038\/s41416-023-02276-0.","journal-title":"Br J Cancer"},{"key":"770_CR22","doi-asserted-by":"publisher","unstructured":"Smith ZD, Hetzel S, Meissner A. DNA methylation in mammalian development and disease. Nat Rev Genet. 2024;1\u201324. https:\/\/doi.org\/10.1038\/s41576-024-00760-8.","DOI":"10.1038\/s41576-024-00760-8"},{"key":"770_CR23","doi-asserted-by":"publisher","unstructured":"Dakal TC, Dhabhai B, Pant A, Moar K, Chaudhary K, Yadav V, et al. Oncogenes and tumor suppressor genes: functions and roles in cancers. Volume 5. MedComm; 2024. p. e582. 6https:\/\/doi.org\/10.1002\/mco2.582.","DOI":"10.1002\/mco2.582"},{"issue":"18","key":"770_CR24","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/cancers13184507","volume":"13","author":"M Piipponen","year":"2021","unstructured":"Piipponen M, Riihil\u00e4 P, Nissinen L, K\u00e4h\u00e4ri VM. The role of p53 in progression of cutaneous squamous cell carcinoma. Cancers. 2021;13(18):4507. https:\/\/doi.org\/10.3390\/cancers13184507.","journal-title":"Cancers"},{"key":"770_CR25","doi-asserted-by":"publisher","first-page":"652160","DOI":"10.3389\/fimmu.2021.652160","volume":"12","author":"K Maes","year":"2021","unstructured":"Maes K, Mondino A, Lasarte JJ, Agirre X, Vanderkerken K, Prosper F, et al. Epigenetic modifiers: anti-neoplastic drugs with Immunomodulating potential. Front Immunol. 2021;12:652160. https:\/\/doi.org\/10.3389\/fimmu.2021.652160.","journal-title":"Front Immunol"},{"key":"770_CR26","doi-asserted-by":"publisher","unstructured":"Sharma M, Sidhu AK, Samota MK, Gupta M, Koli P, Choudhary M. Post-Translational modifications in histones and their role in abiotic stress tolerance in plants. Proteomes. 2023;11(4):38. https:\/\/doi.org\/10.3390\/proteomes11040038.","DOI":"10.3390\/proteomes11040038"},{"key":"770_CR27","doi-asserted-by":"publisher","unstructured":"Luo H, Shan J, Zhang H, Song G, Li Q, Xu CX. Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer. In Seminars in Cancer Biology (Vol. 86, pp. 960\u2013970). Academic Press. (2022). https:\/\/doi.org\/10.1016\/j.semcancer.2022.02.018","DOI":"10.1016\/j.semcancer.2022.02.018"},{"issue":"9","key":"770_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","volume":"23","author":"G Mill\u00e1n-Zambrano","year":"2022","unstructured":"Mill\u00e1n-Zambrano G, Burton A, Bannister AJ, Schneider R. Histone post-translational modifications\u2014cause and consequence of genome function. Nat Rev Genet. 2022;23(9):563\u201380. https:\/\/doi.org\/10.1038\/s41576-022-00468-7.","journal-title":"Nat Rev Genet"},{"key":"770_CR29","doi-asserted-by":"publisher","unstructured":"Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021;57:100770. https:\/\/doi.org\/10.1016\/j.drup.2021.100770.","DOI":"10.1016\/j.drup.2021.100770"},{"key":"770_CR30","doi-asserted-by":"crossref","unstructured":"Rytk\u00f6nen KT, Faux T, Mahmoudian M, Heinosalo T, Nnamani MC, Perheentupa A et al. Histone H3K4me3 breadth in hypoxia reveals endometrial core functions and stress adaptation linked to endometriosis. Iscience. (2022);25(5).","DOI":"10.1016\/j.isci.2022.104235"},{"key":"770_CR31","doi-asserted-by":"crossref","unstructured":"Zhao P, Malik S. The phosphorylation to acetylation\/methylation cascade in transcriptional regulation: how kinases regulate transcriptional activities of DNA\/histone-modifying enzymes. Cell & Bioscience. (2022);12(1):83.","DOI":"10.1186\/s13578-022-00821-7"},{"key":"770_CR32","doi-asserted-by":"publisher","unstructured":"Kawaf RR, Ramadan WS, El-Awady R. Deciphering the interplay of histone post-translational modifications in cancer: Co-targeting histone modulators for precision therapy. Life Sci. 2024;122639. https:\/\/doi.org\/10.1016\/j.lfs.2024.122639.","DOI":"10.1016\/j.lfs.2024.122639"},{"issue":"7","key":"770_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41568-021-00357-x","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao S, Allis CD, Wang GG. The Language of chromatin modification in human cancers. Nat Rev Cancer. 2021;21(7):413\u201330. https:\/\/doi.org\/10.1038\/s41568-021-00357-x.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"770_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/ncrna7010003","volume":"7","author":"M Sebastian-delaCruz","year":"2021","unstructured":"Sebastian-delaCruz M, Gonzalez-Moro I, Olazagoitia-Garmendia A, Castellanos-Rubio A, Santin I. The role of LncRNAs in gene expression regulation through mRNA stabilization. Non-coding RNA. 2021;7(1):3. https:\/\/doi.org\/10.3390\/ncrna7010003.","journal-title":"Non-coding RNA"},{"issue":"10","key":"770_CR35","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.3390\/ijms23105801","volume":"23","author":"IV Bure","year":"2022","unstructured":"Bure IV, Nemtsova MV, Kuznetsova EB. Histone modifications and non-coding rnas: mutual epigenetic regulation and role in pathogenesis. Int J Mol Sci. 2022;23(10):5801. https:\/\/doi.org\/10.3390\/ijms23105801.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"770_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13578-024-01270-0","volume":"14","author":"R Han","year":"2024","unstructured":"Han R, Zhu D, Sha J, Zhao B, Jin P, Meng C. Decoding the role of DNA methylation in allergic diseases: from pathogenesis to therapy. Cell Biosci. 2024;14(1):89. https:\/\/doi.org\/10.1186\/s13578-024-01270-0.","journal-title":"Cell Biosci"},{"issue":"3","key":"770_CR37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/cells11030535","volume":"11","author":"G Furlan","year":"2022","unstructured":"Furlan G, Galupa R. Mechanisms of choice in X-chromosome inactivation. Cells. 2022;11(3):535. https:\/\/doi.org\/10.3390\/cells11030535.","journal-title":"Cells"},{"key":"770_CR38","doi-asserted-by":"publisher","unstructured":"Zhang H, Guo W, Xu W, Li A, Jiang L, Li L. Electrostatic interactions in nucleosome and higher-order structures are regulated by protonation state of histone ionizable residue. BioRxiv. 2024;2024\u201306. https:\/\/doi.org\/10.1101\/2024.06.07.597724.","DOI":"10.1101\/2024.06.07.597724"},{"issue":"1","key":"770_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/19491034.2022.2038868","volume":"13","author":"RK Jha","year":"2022","unstructured":"Jha RK, Levens D, Kouzine F. Mechanical determinants of chromatin topology and gene expression. Nucleus. 2022;13(1):95\u2013116. https:\/\/doi.org\/10.1080\/19491034.2022.2038868.","journal-title":"Nucleus"},{"issue":"11","key":"770_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12032-024-02528-w","volume":"41","author":"AQ Khaleel","year":"2024","unstructured":"Khaleel AQ, Alshahrani MY, Rizaev JA, Malathi H, Devi S, Pramanik A, et al. siRNA-based strategies to combat drug resistance in gastric cancer. Med Oncol. 2024;41(11):293. https:\/\/doi.org\/10.1007\/s12032-024-02528-w.","journal-title":"Med Oncol"},{"issue":"12","key":"770_CR41","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1016\/j.jid.2021.04.023","volume":"141","author":"JR Cortes","year":"2021","unstructured":"Cortes JR, Patrone CC, Quinn SA, Gu Y, Sanchez-Martin M, Mackey A, et al. Jak-STAT Inhibition mediates Romidepsin and mechlorethamine synergism in cutaneous T-cell lymphoma. J Invest Dermatology. 2021;141(12):2908\u201320. https:\/\/doi.org\/10.1016\/j.jid.2021.04.023.","journal-title":"J Invest Dermatology"},{"issue":"2","key":"770_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1210\/er.2004-0008","volume":"26","author":"DY Lee","year":"2005","unstructured":"Lee DY, Teyssier C, Strahl BD, Stallcup MR. Role of protein methylation in regulation of transcription. Endocr Rev. 2005;26(2):147\u201370.","journal-title":"Endocr Rev"},{"key":"770_CR43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/bs.pmbts.2023.01.011","volume":"197","author":"A Roy","year":"2023","unstructured":"Roy A, Chakraborty S, Mishra J, Singh SP, Patra SK. Mechanistic aspects of reversible methylation modifications of arginine and lysine of nuclear histones and their roles in human colon cancer. Prog Mol Biol Transl Sci. 2023;197:261\u2013302. https:\/\/doi.org\/10.1016\/bs.pmbts.2023.01.011.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"6","key":"770_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2022.5360","volume":"60","author":"T Tan","year":"2022","unstructured":"Tan T, Shi P, Abbas MN, Wang Y, Xu J, Chen Y, et al. Epigenetic modification regulates tumor progression and metastasis through EMT. Int J Oncol. 2022;60(6):1\u201317.","journal-title":"Int J Oncol"},{"key":"770_CR45","doi-asserted-by":"publisher","first-page":"175590","DOI":"10.1016\/j.ejphar.2023.175590","volume":"944","author":"LL Marzochi","year":"2023","unstructured":"Marzochi LL, Cuzziol CI, Do Nascimento Filho CHV, Dos Santos JA, Castanhole-Nunes MMU, Pavarino EC, et al. Use of histone methyltransferase inhibitors in cancer treatment: A systematic review. Eur J Pharmacol. 2023;944:175590.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"770_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s43556-023-00161-z","volume":"5","author":"M Tao","year":"2024","unstructured":"Tao M, Shi Y, Chen H, Li J, Wang Y, Ma X, et al. The disruptor of telomeric Silencing 1-like (DOT1L) promotes peritoneal fibrosis through the upregulation and activation of protein tyrosine kinases. Mol Biomed. 2024;5(1):3. https:\/\/doi.org\/10.1186\/s43556-023-00161-z.","journal-title":"Mol Biomed"},{"key":"770_CR47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cbpa.2021.03.002","volume":"63","author":"IA Engelberg","year":"2021","unstructured":"Engelberg IA, Foley CA, James LI, Frye SV. Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine. Curr Opin Chem Biol. 2021;63:132\u201344. https:\/\/doi.org\/10.1016\/j.cbpa.2021.03.002.","journal-title":"Curr Opin Chem Biol"},{"key":"770_CR48","doi-asserted-by":"publisher","unstructured":"Wahi A, Manchanda N, Jain P, Jadhav HR. Targeting the epigenetic reader BET as a therapeutic strategy for cancer. Bioorg Chem. 2023;106833. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106833.","DOI":"10.1016\/j.bioorg.2023.106833"},{"issue":"03","key":"770_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pccm.2023.07.001","volume":"1","author":"J Wallbillich","year":"2023","unstructured":"Wallbillich J, Lu H. Role of c-Myc in lung cancer: progress, challenges, and prospects. Chin Med J Pulmonary Crit Care Med. 2023;1(03):129\u201338.","journal-title":"Chin Med J Pulmonary Crit Care Med"},{"issue":"1","key":"770_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","volume":"6","author":"N Wang","year":"2021","unstructured":"Wang N, Wu R, Tang D, Kang R. The BET family in immunity and disease. Signal Transduct Target Ther. 2021;6(1):23. https:\/\/doi.org\/10.1038\/s41392-020-00384-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"770_CR51","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1002\/1878-0261.13319","volume":"16","author":"G Donati","year":"2022","unstructured":"Donati G, Amati B. MYC and therapy resistance in cancer: risks and opportunities. Mol Oncol. 2022;16(21):3828\u201354.","journal-title":"Mol Oncol"},{"key":"770_CR52","doi-asserted-by":"publisher","unstructured":"Faskhoudi MA, Molaei P, Sadrkhanloo M, Orouei S, Hashemi M, Bokaie S, et al. Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation. Pathol Res Pract. 2022;233:153851. https:\/\/doi.org\/10.1016\/j.prp.2022.153851.","DOI":"10.1016\/j.prp.2022.153851"},{"issue":"1","key":"770_CR53","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal Transduct Target Ther. 2023;8(1):420. https:\/\/doi.org\/10.1038\/s41392-023-01647-6.","journal-title":"Signal Transduct Target Ther"},{"key":"770_CR54","doi-asserted-by":"publisher","unstructured":"Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress. In Seminars in Cancer Biology (Vol. 83, pp. 452\u2013471). Academic Press. (2022). https:\/\/doi.org\/10.1016\/j.semcancer.2020.07.015","DOI":"10.1016\/j.semcancer.2020.07.015"},{"issue":"5","key":"770_CR55","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/febs.15750","volume":"289","author":"S Feng","year":"2022","unstructured":"Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 2022;289(5):1214\u201339. https:\/\/doi.org\/10.1111\/febs.15750.","journal-title":"FEBS J"},{"key":"770_CR56","doi-asserted-by":"publisher","unstructured":"Lanzi C, Arrighetti N, Pasquali S, Cassinelli G. Targeting EZH2 in SMARCB1-deficient sarcomas: advances and opportunities to potentiate the efficacy of EZH2 inhibitors. Biochem Pharmacol. 2023;115727. https:\/\/doi.org\/10.1016\/j.bcp.2023.115727.","DOI":"10.1016\/j.bcp.2023.115727"},{"issue":"16","key":"770_CR57","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.3390\/cancers14164050","volume":"14","author":"PA Lazo","year":"2022","unstructured":"Lazo PA. Targeting histone epigenetic modifications and DNA damage responses in synthetic lethality strategies in cancer? Cancers. 2022;14(16):4050. https:\/\/doi.org\/10.3390\/cancers14164050.","journal-title":"Cancers"},{"issue":"8","key":"770_CR58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood.2019004262","volume":"138","author":"HT Huang","year":"2021","unstructured":"Huang HT, Figueroa ME. Epigenetic deregulation in myeloid malignancies. Blood. J Am Soc Hematol. 2021;138(8):613\u201324. https:\/\/doi.org\/10.1182\/blood.2019004262.","journal-title":"J Am Soc Hematol"},{"key":"770_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-020-00860-2","volume":"12","author":"S Banday","year":"2020","unstructured":"Banday S, Farooq Z, Ganai SA, Altaf M. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias. Clin Epigenetics. 2020;12:1\u20139. https:\/\/doi.org\/10.1186\/s13148-020-00860-2.","journal-title":"Clin Epigenetics"},{"issue":"2","key":"770_CR60","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41419-023-05656-9","volume":"14","author":"D Wu","year":"2023","unstructured":"Wu D, Shi Y, Zhang H, Miao C. Epigenetic mechanisms of immune remodeling in sepsis: targeting histone modification. Cell Death Dis. 2023;14(2):112. https:\/\/doi.org\/10.1038\/s41419-023-05656-9.","journal-title":"Cell Death Dis"},{"issue":"10","key":"770_CR61","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1172\/JCI120518","volume":"128","author":"D Su","year":"2018","unstructured":"Su D, Ma S, Shan L, Wang Y, Wang Y, Cao C, et al. Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis. J Clin Investig. 2018;128(10):4280\u201396.","journal-title":"J Clin Investig"},{"issue":"1","key":"770_CR62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12672-022-00579-x","volume":"13","author":"S Caporali","year":"2022","unstructured":"Caporali S, Butera A, Amelio I. BAP1 in cancer: epigenetic stability and genome integrity. Discover Oncol. 2022;13(1):117. https:\/\/doi.org\/10.1007\/s12672-022-00579-x.","journal-title":"Discover Oncol"},{"issue":"1","key":"770_CR63","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13578-024-01291-9","volume":"14","author":"Z Feng","year":"2024","unstructured":"Feng Z, Ou Y, Deng X, Deng M, Yan X, Chen L, et al. Deubiquitinase USP10 promotes osteosarcoma autophagy and progression through regulating GSK3\u03b2-ULK1 axis. Cell Bioscience. 2024;14(1):111. https:\/\/doi.org\/10.1186\/s13578-024-01291-9.","journal-title":"Cell Bioscience"},{"issue":"12","key":"770_CR64","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.3390\/ijms22126213","volume":"22","author":"S Moon","year":"2021","unstructured":"Moon S, Muniyappan S, Lee SB, Lee BH. Small-molecule inhibitors targeting proteasome-associated deubiquitinases. Int J Mol Sci. 2021;22(12):6213. https:\/\/doi.org\/10.3390\/ijms22126213.","journal-title":"Int J Mol Sci"},{"key":"770_CR65","doi-asserted-by":"publisher","first-page":"117955492412819","DOI":"10.1177\/11795549241281932","volume":"18","author":"J Wang","year":"2024","unstructured":"Wang J, Fang S, Jiang Y, Hua. Unraveling the mechanism of action of Ubiquitin-Specific protease 5 and its inhibitors in tumors. Clin Med Insights: Oncol. 2024;18:11795549241281932. https:\/\/doi.org\/10.1177\/11795549241281932.","journal-title":"Clin Med Insights: Oncol"},{"key":"770_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-021-00721-x","volume":"28","author":"K Nepali","year":"2021","unstructured":"Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J Biomed Sci. 2021;28:1\u201358. https:\/\/doi.org\/10.1186\/s12929-021-00721-x.","journal-title":"J Biomed Sci"},{"issue":"5","key":"770_CR67","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/cbdd.14135","volume":"100","author":"NNJ Basha","year":"2022","unstructured":"Basha NNJ, Basavarajaiah SM. An insight into therapeutic efficacy of heterocycles as histone-modifying enzyme inhibitors that targets cancer epigenetic pathways. Chem Biol Drug Des. 2022;100(5):682\u201398. https:\/\/doi.org\/10.1111\/cbdd.14135.","journal-title":"Chem Biol Drug Des"},{"issue":"17","key":"770_CR68","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.3390\/molecules26175300","volume":"26","author":"C Bon","year":"2021","unstructured":"Bon C, Si Y, Pernak M, Barbachowska M, Levi-Acobas E, Cadet Daniel V, et al. Synthesis and biological activity of a cytostatic inhibitor of MLLr leukemia targeting the DOT1L protein. Molecules. 2021;26(17):5300. https:\/\/doi.org\/10.3390\/molecules26175300.","journal-title":"Molecules"},{"key":"770_CR69","doi-asserted-by":"publisher","unstructured":"Zhang S, Liu M, Yao Y, Yu B, Liu H. Targeting LSD1 for acute myeloid leukemia (AML) treatment. Pharmacol Res. 2021;164. https:\/\/doi.org\/10.1016\/j.phrs.2020.105335.","DOI":"10.1016\/j.phrs.2020.105335"},{"key":"770_CR70","doi-asserted-by":"publisher","unstructured":"Cheung KL, Kim C, Zhou MM. The functions of BET proteins in gene transcription of biology and diseases. Front Mol Biosci. 2021;8. https:\/\/doi.org\/10.3389\/fmolb.2021.728777.","DOI":"10.3389\/fmolb.2021.728777"},{"issue":"12","key":"770_CR71","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-22-0591","volume":"28","author":"CA French","year":"2022","unstructured":"French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, et al. Report of the first international symposium on NUT carcinoma. Clin Cancer Res. 2022;28(12):2493\u2013505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0591.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"770_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.9628","volume":"21","author":"V Mpakou","year":"2021","unstructured":"Mpakou V, Spathis A, Bouhla A, Mpazani E, Papageorgiou S, Gkontopoulos K, et al. Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1. Exp Ther Med. 2021;21(3):1\u20131. https:\/\/doi.org\/10.3892\/etm.2021.9628.","journal-title":"Exp Ther Med"},{"issue":"18","key":"770_CR73","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.3390\/cancers13184700","volume":"13","author":"A Wawruszak","year":"2021","unstructured":"Wawruszak A, Borkiewicz L, Okon E, Kukula-Koch W, Afshan S, Halasa M. Vorinostat (SAHA) and breast cancer: an overview. Cancers. 2021;13(18):4700.","journal-title":"Cancers"},{"key":"770_CR74","doi-asserted-by":"publisher","unstructured":"Omari NE, Lee LH, Bakrim S, Makeen HA, Alhazmi HA, Mohan S, et al. Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of Romidepsin. Biomed Pharmacother. 2023;164. https:\/\/doi.org\/10.1016\/j.biopha.2023.114774.","DOI":"10.1016\/j.biopha.2023.114774"},{"issue":"9","key":"770_CR75","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/14656566.2021.1882997","volume":"22","author":"A Wolska-Washer","year":"2021","unstructured":"Wolska-Washer A, Smolewski P, Robak T. Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma. Expert Opin Pharmacother. 2021;22(9):1203\u201315. https:\/\/doi.org\/10.1080\/14656566.2021.1882997.","journal-title":"Expert Opin Pharmacother"},{"issue":"17","key":"770_CR76","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2217\/fon-2020-1244","volume":"17","author":"E Julia","year":"2021","unstructured":"Julia E, Salles G. EZH2 Inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma. Future Oncol. 2021;17(17):2127\u201340. https:\/\/doi.org\/10.2217\/fon-2020-1244.","journal-title":"Future Oncol"},{"key":"770_CR77","doi-asserted-by":"crossref","unstructured":"Stemer G, Rowe JM, Ofran Y. Efficacy and safety profile of Ivosidenib in the management of patients with acute myeloid leukemia (AML): an update on the emerging evidence. Blood Lymphat Cancer. 2021:41\u201354.","DOI":"10.2147\/BLCTT.S236446"},{"key":"770_CR78","doi-asserted-by":"publisher","unstructured":"Zheng S, Barczak W, Liu G, Thangue NL. Histone Deacetylases. 2024. https:\/\/doi.org\/10.1039\/9781837674916-00228.","DOI":"10.1039\/9781837674916-00228"},{"issue":"12","key":"770_CR79","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.3390\/cancers14122978","volume":"14","author":"L Taiarol","year":"2022","unstructured":"Taiarol L, Bigogno C, Sesana S, Kravicz M, Viale F, Pozzi E, et al. Givinostat-liposomes: anti-tumor effect on 2D and 3D glioblastoma models and pharmacokinetics. Cancers. 2022;14(12):2978. https:\/\/doi.org\/10.3390\/cancers14122978.","journal-title":"Cancers"},{"key":"770_CR80","doi-asserted-by":"publisher","first-page":"628415","DOI":"10.3389\/fcell.2021.628415","volume":"9","author":"S Kumar","year":"2021","unstructured":"Kumar S, Mohapatra T. Deciphering epitranscriptome: modification of mRNA bases provides a new perspective for post-transcriptional regulation of gene expression. Front Cell Dev Biol. 2021;9:628415. https:\/\/doi.org\/10.3389\/fcell.2021.628415.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"770_CR81","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41420-022-00947-0","volume":"8","author":"J Liao","year":"2022","unstructured":"Liao J, Wei Y, Liang J, Wen J, Chen X, Zhang B, et al. Insight into the structure, physiological function, and role in cancer of m6A readers\u2014YTH domain-containing proteins. Cell Death Discovery. 2022;8(1):137. https:\/\/doi.org\/10.1038\/s41420-022-00947-0.","journal-title":"Cell Death Discovery"},{"key":"770_CR82","doi-asserted-by":"publisher","unstructured":"Uddin MB, Wang Z, Yang C. Roles of m 6 A RNA modification in normal development and disease. Epitranscriptomics. 2021;267\u2013308. https:\/\/doi.org\/10.1007\/978-3-030-71612-7_10.","DOI":"10.1007\/978-3-030-71612-7_10"},{"issue":"6","key":"770_CR83","doi-asserted-by":"publisher","first-page":"101119","DOI":"10.1016\/j.cossms.2023.101119","volume":"27","author":"L Sun","year":"2023","unstructured":"Sun L, Zuo Z, Qiu X, Wang G, Li Q, Qiu J, et al. Recent advances in the interplay between stress granules and m6A RNA modification. Curr Opin Solid State Mater Sci. 2023;27(6):101119. https:\/\/doi.org\/10.1016\/j.cossms.2023.101119.","journal-title":"Curr Opin Solid State Mater Sci"},{"key":"770_CR84","doi-asserted-by":"publisher","unstructured":"Lothion-Roy J, Haigh DB, Harris AE, Metzler VM, Alsaleem M, Toss MS, et al. Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. Front Genet. 2023;13p1096071. https:\/\/doi.org\/10.3389\/fgene.2022.1096071.","DOI":"10.3389\/fgene.2022.1096071"},{"issue":"1","key":"770_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43556-024-00234-7","volume":"5","author":"Z Wang","year":"2024","unstructured":"Wang Z, Du X, Zhang P, Zhao M, Zhang T, Liu J, et al. Single-cell transcriptome profiling of m6A regulator-mediated methylation modification patterns in elderly acute myeloid leukemia patients. Mol Biomed. 2024;5(1):1\u201320.","journal-title":"Mol Biomed"},{"key":"770_CR86","doi-asserted-by":"publisher","unstructured":"Chen Y, Jiang Z, Yang Y, Zhang C, Liu H, Wan J. The functions and mechanisms of post-translational modification in protein regulators of RNA methylation: current status and future perspectives. Int J Biol Macromol. 2023;126773. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.126773.","DOI":"10.1016\/j.ijbiomac.2023.126773"},{"issue":"sup1","key":"770_CR87","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/15476286.2021.1950993","volume":"18","author":"Y Gao","year":"2021","unstructured":"Gao Y, Fang J. RNA 5-methylcytosine modification and its emerging role as an epitranscriptomic mark. RNA Biol. 2021;18(sup1):117\u201327. https:\/\/doi.org\/10.1080\/15476286.2021.1950993.","journal-title":"RNA Biol"},{"key":"770_CR88","first-page":"284","volume":"8","author":"A Khan","year":"2023","unstructured":"Khan A, Hu YD, Khan S, Aqeel SM, Khan I, Hussain M, et al. Pseudouridine in RNA: enzymatic synthesis mechanisms and functional roles in molecular biology. Int J Environ Agric Biotechnol. 2023;8:284\u2013300.","journal-title":"Int J Environ Agric Biotechnol"},{"issue":"18","key":"770_CR89","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/1873-3468.14188","volume":"595","author":"TY Lin","year":"2021","unstructured":"Lin TY, Mehta R, Glatt S. Pseudouridines in rnas: switching atoms means shifting paradigms. FEBS Lett. 2021;595(18):2310\u201322. https:\/\/doi.org\/10.1002\/1873-3468.14188.","journal-title":"FEBS Lett"},{"key":"770_CR90","doi-asserted-by":"publisher","first-page":"p1465546","DOI":"10.3389\/fcell.2024.1465546","volume":"12","author":"K Liu","year":"2024","unstructured":"Liu K, Zhang S, Liu Y, Hu X, Gu X. Advancements in Pseudouridine modifying enzyme and cancer. Front Cell Dev Biol. 2024;12:p1465546. https:\/\/doi.org\/10.3389\/fcell.2024.1465546.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"770_CR91","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.tips.2022.03.008","volume":"43","author":"J Cerneckis","year":"2022","unstructured":"Cerneckis J, Cui Q, He C, Yi C, Shi Y. Decoding pseudouridine: an emerging target for therapeutic development. Trends Pharmacol Sci. 2022;43(6):522\u201335.","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"770_CR92","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1261\/rna.079970.124","volume":"30","author":"KI Zhou","year":"2024","unstructured":"Zhou KI, Pecot CV, Holley CL. 2\u2032-O-methylation (Nm) in RNA: progress, challenges, and future directions. RNA. 2024;30(5):570\u201382.","journal-title":"RNA"},{"key":"770_CR93","doi-asserted-by":"publisher","unstructured":"Minasov G, Rosas-Lemus M, Shuvalova L, Inniss NL, Brunzelle JS, Daczkowski CM et al. Mn2\u2009+\u2009coordinates Cap-0-RNA to align substrates for efficient $$2^\\prime$$-O-methyl transfer by SARS-CoV-2 nsp16. Science signaling. (2021);14(689):eabh2071. https:\/\/doi.org\/10.1126\/scisignal.abh2071.","DOI":"10.1126\/scisignal.abh2071"},{"issue":"1","key":"770_CR94","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/cells10010110","volume":"10","author":"AMMT Reza","year":"2021","unstructured":"Reza AMMT, Yuan YG. MicroRNAs mediated regulation of the ribosomal proteins and its consequences on the global translation of proteins. Cells. 2021;10(1):110. https:\/\/doi.org\/10.3390\/cells10010110.","journal-title":"Cells"},{"issue":"22","key":"770_CR95","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1021\/acs.accounts.3c00433","volume":"56","author":"LP Keegan","year":"2023","unstructured":"Keegan LP, Hajji K, O\u2019Connell MA. Adenosine deaminase acting on RNA (ADAR) enzymes: a journey from Weird to wondrous. Acc Chem Res. 2023;56(22):3165\u201374.","journal-title":"Acc Chem Res"},{"key":"770_CR96","doi-asserted-by":"publisher","unstructured":"Kim HS, Eun JW, Jang SH, Kim JY, Jeong JY. The diverse landscape of RNA modifications in cancer development and progression. Genes & Genomics; 2024. pp. 1\u201321. https:\/\/doi.org\/10.1007\/s13258-024-01601-y.","DOI":"10.1007\/s13258-024-01601-y"},{"key":"770_CR97","doi-asserted-by":"crossref","unstructured":"Bao C, Ma Q, Ying X, Wang F, Hou Y, Wang D et al. Histone lactylation in macrophage biology and disease: from plasticity regulation to therapeutic implications. EBioMedicine. (2025):111.","DOI":"10.1016\/j.ebiom.2024.105502"},{"issue":"10","key":"770_CR98","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/genes12101596","volume":"12","author":"V Cavalieri","year":"2021","unstructured":"Cavalieri V. The expanding constellation of histone post-translational modifications in the epigenetic landscape. Genes. 2021;12(10):1596. https:\/\/doi.org\/10.3390\/genes12101596.","journal-title":"Genes"},{"key":"770_CR99","doi-asserted-by":"publisher","first-page":"p949252","DOI":"10.3389\/fgene.2022.949252","volume":"13","author":"Y Xie","year":"2022","unstructured":"Xie Y, Hu H, Liu M, Zhou T, Cheng X, Huang W, et al. The role and mechanism of histone lactylation in health and diseases. Front Genet. 2022;13:p949252.","journal-title":"Front Genet"},{"issue":"5","key":"770_CR100","doi-asserted-by":"publisher","first-page":"101060","DOI":"10.1016\/j.gendis.2023.06.029","volume":"11","author":"H Zhao","year":"2024","unstructured":"Zhao H, Han Y, Zhou P, Guan H, Gao S. Protein lysine crotonylation in cellular processions and disease associations. Genes Dis. 2024;11(5):101060. https:\/\/doi.org\/10.1016\/j.gendis.2023.06.029.","journal-title":"Genes Dis"},{"issue":"21","key":"770_CR101","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3390\/cells13211812","volume":"13","author":"S Yang","year":"2024","unstructured":"Yang S, Fan X, Yu W. Regulatory mechanism of protein crotonylation and its relationship with cancer. Cells. 2024;13(21):1812. https:\/\/doi.org\/10.3390\/cells13211812.","journal-title":"Cells"},{"key":"770_CR102","doi-asserted-by":"publisher","unstructured":"Hoareau M, Gerges E, Cr\u00e9mazy FG. Shedding Light on Bacterial Chromosome Structure: Exploring the Significance of 3\u00a0C-Based Approaches. Bacterial Chromatin: Methods Protocols. 2024;3\u201326. https:\/\/doi.org\/10.1007\/978-1-0716-3930-6_1.","DOI":"10.1007\/978-1-0716-3930-6_1"},{"key":"770_CR103","doi-asserted-by":"publisher","unstructured":"Kumar S, Kaur S, Seem K, Kumar S, Mohapatra T. Understanding 3D genome organization and its effect on transcriptional gene regulation under environmental stress in plant: a chromatin perspective. Front Cell Dev Biol. 2021;9. https:\/\/doi.org\/10.3389\/fcell.2021.774719.","DOI":"10.3389\/fcell.2021.774719"},{"key":"770_CR104","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/cancers10120483","volume":"10","author":"M Leary","year":"2018","unstructured":"Leary M, Heerboth S, Lapinska K, Sarkar S. Sensitization of Drug-Resistant cancer cells: A matter of combination therapy. Cancers. 2018;10:483. https:\/\/doi.org\/10.3390\/cancers10120483.","journal-title":"Cancers"},{"key":"770_CR105","doi-asserted-by":"publisher","first-page":"1213513","DOI":"10.3389\/fonc.2023.1213513","volume":"13","author":"H-Y Chan","year":"2023","unstructured":"Chan H-Y, Chan MWY, Lui VWY, Kuppen PJK, Hung S-K. Editorial: the role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application. Front Oncol. 2023;13:1213513. https:\/\/doi.org\/10.3389\/fonc.2023.1213513.","journal-title":"Front Oncol"},{"issue":"12","key":"770_CR106","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","volume":"21","author":"JD Chan","year":"2021","unstructured":"Chan JD, Lai J, Slaney CY, Kallies A, Beavis PA, Darcy PK. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat Rev Immunol. 2021;21(12):769\u201384. https:\/\/doi.org\/10.1038\/s41577-021-00539-6.","journal-title":"Nat Rev Immunol"},{"key":"770_CR107","doi-asserted-by":"publisher","first-page":"115331","DOI":"10.1016\/j.biopha.2023.115331","volume":"166","author":"H Tian","year":"2023","unstructured":"Tian H, Zhao F, Qi Q, Yue B, Zhai B. Targeted drug delivery systems for elemene in cancer therapy: the story thus Far. Biomed Pharmacother. 2023;166:115331. https:\/\/doi.org\/10.1016\/j.biopha.2023.115331.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"770_CR108","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237\u201351. https:\/\/doi.org\/10.1038\/nrc3237.","journal-title":"Nat Rev Cancer"},{"key":"770_CR109","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ymeth.2020.04.006","volume":"187","author":"MM Rahman","year":"2021","unstructured":"Rahman MM, Tollefsbol TO. Targeting cancer epigenetics with CRISPR-dCAS9: principles and prospects. Methods. 2021;187:77\u201391. https:\/\/doi.org\/10.1016\/j.ymeth.2020.04.006.","journal-title":"Methods"},{"issue":"1","key":"770_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li H, Yang Y, Hong W, Huang M, Wu M, et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5(1):1. https:\/\/doi.org\/10.1038\/s41392-019-0089-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"770_CR111","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel D, Jeffery D, Aspeslagh S, Almouzni G. Postel-Vinay. Combining epigenetic drugs with other therapies for solid tumours\u2014past lessons and future promise. Nat Rev Clin Oncol. 2020;17(2):91\u2013107. https:\/\/doi.org\/10.1038\/s41571-019-0267-4.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00770-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00770-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00770-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:16:13Z","timestamp":1768342573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00770-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00770-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}